AC
NVO

Arrow Capital’s Novo Nordisk NVO Stock Holding History

Arrow Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-130,000
Closed -$6.61M – 25
2025
Q4 		$6.61M Buy
130,000
+60,000
+86% +$3.07M 6.34% 8
2025
Q3 		$5.87M Buy
+70,000
New +$4.1M 3.15% 20
2025
Q1 		– Sell
-30,000
Closed -$2.58M – 37
2024
Q4 		$2.58M Buy
+30,000
New +$3.24M 2.36% 21

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Arrow Capital's NVO Position: Q1 2026 in Review

Arrow Capital sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 130,000 shares — an estimated $6.61M sold.

Arrow Capital first reported a position in NVO in Q4 2024 and held it in 3 quarters. The position peaked at $6.61M in Q4 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Arrow Capital reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Arrow Capital sold 130,000 Novo Nordisk shares in Q1 2026, an estimated $6.61M.
  • Arrow Capital first reported a position in Novo Nordisk in Q4 2024 and held it in 3 quarters.
  • Arrow Capital's Novo Nordisk position peaked at $6.61M in Q4 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Arrow Capital's 13F filing for Q1 2026, filed 12 May 2026.